Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 bởi

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023 bởi

Several factors contribute to potentially inappropriate prescribing (PIP) among older persons in primary care settings, and these elements can be classified into patient, physician, and system, according to a Singapore study. These factors can help in designing complex interventions for PIP and in developing risk prediction tools to identify groups who may need further PIP-related interventions.

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Brolucizumab helps improve visual and anatomic outcomes in diabetic macular edema (DME), with long-term efficacy and durability and no new safety signals, as shown in the 100-week data from the phase III KESTREL and KITE studies.

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

A new lotion formulation of 20% oxybutynin hydrochloride (20% OL) demonstrates efficacy in reducing palmar sweat volume among patients with primary palmar hyperhidrosis (PPHH) when compared with placebo, results of a phase III study have shown.

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023 bởi

Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023

Theophylline shows promise in SCI-induced bradycardia

18 Jul 2023

Use of theophylline as an adjunctive therapy appears to lead to favourable outcomes among patients with bradycardia due to acute spinal cord injury (SCI) with an acceptable response to this agent, suggest the results of a study.

Theophylline shows promise in SCI-induced bradycardia

18 Jul 2023

Phase III data support long-term efficacy of TAF against HBV

18 Jul 2023 bởi

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).

Phase III data support long-term efficacy of TAF against HBV

18 Jul 2023

RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy

17 Jul 2023

In the treatment of rheumatoid arthritis (RA), more patients achieve clinical remission with abatacept or certolizumab pegol, but not with tocilizumab, than with active conventional therapy, according to a study.

RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy

17 Jul 2023

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023 bởi

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Baseline HbA1c strongly predicts metformin failure

Baseline HbA1c strongly predicts metformin failure

Which factors promote inappropriate prescribing among older patients in primary care?

Which factors promote inappropriate prescribing among older patients in primary care?

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Novel lotion formulation helps reduce palm sweating

Novel lotion formulation helps reduce palm sweating

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

Theophylline shows promise in SCI-induced bradycardia

Theophylline shows promise in SCI-induced bradycardia

Phase III data support long-term efficacy of TAF against HBV

Phase III data support long-term efficacy of TAF against HBV

RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy

RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial